PCT
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 51/08

(11) International Publication Number: WO 00/48639
(43) International Publication Date: 24 August 2000 (24.08.00)

(21) International Application Number: PCT/CA99/00700
(22) International Filing Date: 3 August 1999 (03.08.99)
(30) Priority Data: 60/120,561 17 February 1999 (17.02.99) US

(71) Applicant (for all designated States except US): RESOLUTION PHARMACEUTICALS INC. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA).

(72) Inventors; and
(75) Inventors/Applicants (for US only): POLLAK, Alfred [CA/ST]; Murnikova 8A, 1000 Ljubljana (SI); ROE, David [GB/CA]; 100 Inkerman Street #7, Rockwood, Ontario N0B 2K0 (CA); LU, Linda, Fung, Ling [CA/CA]; 63 Fawndale Crescent, Scarborough, Ontario M1W 2X3 (CA). THORNBACK, John [GB/CA]; 6 Poplar Plains Crescent, Toronto, Ontario M4V 1B8 (CA); POLLOCK, Catherine, Michelle [CA/CA]; 59 Station Road, Apt. C, Toronto, Ontario M8V 2R2 (CA).

(74) Agent: DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).


Published
With international search report.

(54) Title: IMMOBILIZED LABELING COMPOUNDS AND METHODS

(57) Abstract

The invention includes methods and compounds for labelling conjugates with metals which comprise the steps of coupling the conjugate to a support surface; introducing a complex-forming metal to the support; and collecting the metal-conjugate complex released from the support. The metal catalyzes cleavage of the conjugate from the support upon complex formation resulting in a solutions substantially free of unlabeled conjugate.
For the purposes of information only

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslavia</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d’Ivoire</td>
<td>KP</td>
<td>Democratic People’s Republic of Korea</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td>SI</td>
<td>Slovenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TM</td>
<td>Turkmenistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TR</td>
<td>Turkey</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UG</td>
<td>Uganda</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VN</td>
<td>Viet Nam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YU</td>
<td>Yugoslavia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IMMOBILIZED LABELING COMPOUNDS AND METHODS

FIELD OF THE INVENTION

The invention relates to compounds and methods useful for generating metal-ligand complexes. The metal-labeled agents are useful in radiotherapy and as imaging agents in medical diagnostics.

BACKGROUND

The art of diagnostic imaging exploits compounds that in binding or localizing site selectively within the body, help to resolve the image of diagnostic interest. Diagnostic imaging agents are effective for targeting and imaging biological receptors. These diagnostic imaging agents incorporate radionuclide metals such as technetium and rhenium. The radionuclide metals are used to label targeting molecules, such as proteins, peptides and antibodies that localize at desired regions of the human body. Localization of these agents is detected by gamma camera analysis. As targeting agents, proteins and peptides can offer the tissue specificity required for diagnostic accuracy.

Labeling of these and other diagnostic agents with metal atoms is made difficult by their chemical structure. Conventional labeling techniques involve the formation of the metal complex in a solution of excess ligand which typically results in high levels of unlabelled ligand. For example, technetium labeling reactions yield approximately one labeled ligand for every thousand or more unlabeled ligand. For many radiodiagnostic agents there is a finite number of binding sites i.e. receptors for which both the labeled and unlabeled diagnostic agent compete. This leads to poor imaging because the excess unlabeled ligands compete with the labeled ligands for the binding sites. As a result, the administration of larger doses of the agent is required to achieve an acceptable image. The administration of larger doses of the agent into a patient can lead to adverse effects. Targeting molecules often cause physiological changes when they bind or localize to specific sites. For example, the targeting molecule may be a peptide that binds to a receptor and agonizes or antagonizes receptor activity. Unlabeled peptide will still cause the physiological effect of agonizing or antagonizing receptor activity, however, the benefits of a metal labeled peptide will not be obtained.
Presently, high performance liquid chromatography (HPLC) is applied to enhance the concentration of labeled agent in the solution before it is administered. While enhancing concentration, this separation step requires additional time and expense. This makes the technique impractical for clinical use.

A method for labeling biological targeting molecules with radionuclide metals is described in US patent 5,789,555. The method involves the steps of covalently linking a chelating portion of a biological targeting molecule to a solid support through a metal cleavable maleimide linker. When a radionuclide metal is introduced, it complexes with the chelating portion of the biological targeting molecule. This results in the release of the biological targeting molecule from the support yielding a labeled biological targeting molecule. This method provides a high ratio of labeled to unlabeled molecules (specific activity). However the use of the linker requires an extra step of coupling the linker to the support. The requirement of a linker is therefore a drawback of this method.

Many labeling methods require the formation of the free thiol. The thiols tend react with each other forming disulphides. Extra precautions need to be taken to avoid disulphide formation which results in the reduction of product attached to the surface and the need for extra purification before radiolabeling.

Many metal chelators contain a sulfur atom which participates in the chelating function. Sulfur atoms are commonly rendered unreactive by the use of protecting groups, one of which is acetamidomethyl. The sulfur is protected with an acetamidomethyl group. The sulfur protecting groups must be removed to provide a free thiol. The acetamidomethyl protecting group is removed from the sulfur through the use of mercuric acetate. Mercuric acetate coordinates to the sulfur which then possesses a slightly positive charge making the chelator a good leaving group. The excess mercuric acetate is removed by reaction with hydrogen sulphide. Mercuric acetate is quite toxic. Therefore the requirement to deprotect sulfur with mercuric acetate is a drawback.

The labeling method described in US patent 5,789,555 makes use of organic solid supports that consist of a plurality of particles. The particles can be difficult to filter for the subsequent removal of the unbound and labeled biological targeting molecules. These supports are
very susceptible to radiolytic degradation due the emission of \( \beta \)-particles by certain radionuclide metals. These supports are also otherwise not chemically robust. This makes the solid support difficult to sterilize since sterilization is carried out at very high temperatures.

There is therefore a need for a solid support for labeling biological targeting molecules with a radionuclide metal that permits labeling be carried out in a single step without the need for linker group. There is a need for a solid support for labeling biological targeting molecules with a radionuclide metal that has increased chemical robustness, reduced radiolytic degradation, is easily sterilized, and labeled and has well defined loading characteristics. There is further need for such a solid support that can directly bind a protected thiol group to form a bound thiol thereby avoiding the formation of disulfides.

There is a further need for an improved system that employs a surface as a substitute for mercury so that no mercuric acetate needs to be used or subsequently removed in order to deprotect sulfur atoms. There is a need for such a system that eliminates a few synthetic steps as well as the presence of mercury in a reaction solution.

**SUMMARY OF THE INVENTION**

The invention includes a method of producing metal labeled imaging and radiopharmaceutical agent formulations having high specific activity. The invention includes labeling peptides (such as dimethylglycolylserinylcysteinylyglycine) or other organic molecules that are attached to a support surface, preferably gold, via a group of a molecule that binds the surface. The surface binding molecule is preferably the sulfur group of a cysteine (this cysteine will ultimately be a part of the metal chelate). During the labeling of the peptide with a metal, (which is preferably a radioisotope, such as \( ^{99m} \text{Tc} \)), the complexation of the metal to the chelator, and hence to the sulfur of the cysteine, causes weakening of the gold-cysteine bond with the result that the metal complexed peptide leaves the surface and moves into solution. Uncomplexed peptides remain attached to the gold surface. The result of this selective cleavage from the surface is that the radiolabeled peptide is produced without added carrier giving a high specific activity formulation.
According to one aspect of the present invention, sulfur is initially de-protected to produce the free thiol using mercuric acetate. The de-protected peptide is then added to the gold. However, the gold surface also allows for the in situ formation of the bound thiol. Therefore, according to another aspect of the present invention, a novel method for in situ production of the bound thiol is employed. This method allows protected sulfur groups to be de-protected without having to use mercuric acetate.

This approach to the preparation of radiopharmaceuticals having high specific activity offers the following advantages over the use of polymer supported strategies:

- Increased chemical robustness of the metal support surface
- Elimination of the presence of mercuric acetate
- Avoidance of unnecessary handling of the free thiol
- Elimination of extra synthetic steps
- Production of the bound thiol in situ
- Reduced radiolytic degradation of the metal support surface
- Ease of sterilisation
- Ease of attachment of the HS-chelator-targeting molecule
- Well defined loading characteristics (by virtue of the ability to vary the surface area)

The invention includes a compound useful for generating a complex-forming metal ion labeled agent, the compound including: a metal support surface, and a conjugate releasably bound to the support surface, wherein the conjugate is capable of coordinating with a complex-forming metal ion so that the conjugate is released from the support surface. In a preferred variant, the conjugate includes a ligand and a targeting molecule and the ligand incorporates:
(a) a surface binding group selected from the group consisting of a cysteine amino acid residue, a cysteine amino acid residue derivative, a thiol or thioether group attached to an organic molecule, an amino acid residue derivative including phosphorous and a phosphorous containing organic molecule, wherein the amino acid residue, amino acid residue derivative or organic molecule is capable of releasably binding to the support surface; and

(b) at least one accessory group capable of coordinating with the complex-forming metal ion; wherein the conjugate is capable of coordinating with a complex-forming metal ion so that the conjugate is released from the support surface.

In another embodiment, the invention includes a method for generating a complex-forming metal ion labeled diagnostic agent or radiotherapeutic agent, including the steps of: (a) obtaining a compound according to any of claims 1 to 18; (b) contacting the compound with the complex-forming metal ion to form a coordinate bond between the complex-forming metal ion and the agent so that the complex-forming metal labeled agent is released from the support surface.

One variation of the invention includes a method for generating a complex-forming metal ion labeled diagnostic agent or radiotherapeutic agent, including transchelating a conjugate from a metal support surface to a complex-forming metal ion so that the conjugate is released from the metal support surface. The invention also includes a method for preparing a complex-forming metal ion labeled peptide including (a) bonding a peptide, polypeptide, peptide mimetic or polypeptide mimetic that includes (i) a cysteine amino acid residue, a cysteine amino acid residue derivative or a phosphorous amino acid residue derivative and (ii) at least one accessory group capable of coordinating with the complex-forming metal ion, to a metal support surface by the sulfur atom or phosphorous atom of the residue or derivative and (b) labeling the peptide, polypeptide or mimetic with a complex-forming metal so that the metal complexed peptide, polypeptide or mimetic is released from the support surface. Another aspect of the invention relates to a method for preparing a complex-forming metal ion labeled agent including (a) bonding an organic molecule that includes (i) a sulfur atom or a phosphorous atom and (ii) at least one accessory group capable of coordinating with the complex-forming metal ion, to a support surface by the sulfur atom or the phosphorous atom and (b) labeling the agent with a
complex-forming metal so that the metal complex conjugate is released from the support surface.

The invention also includes a complex-forming metal ion labeled agent prepared according to the methods of the invention as well as compositions and pharmaceutical compositions including the agent. The invention also includes a composition including a technetium metal labeled agent, wherein the composition includes a specific activity greater than 10,000 Ci/mm mol with 99m-technetium and greater than 3,000 Ci/mm mol with 188-rhenium. A pharmaceutical composition for radiotherapy or imaging, including a carrier and a complex-forming metal ion labeled agent, wherein the agent is prepared without HPLC.

Another embodiment of the invention includes a kit for preparing a complex-forming metal ion labeled agent. The kit includes a metal support surface, a conjugate and a predetermined quantity of a complex-forming metal ion. The conjugate is capable of being releasably bound to the support surface and is capable of coordinating with the complex-forming metal ion so that the conjugate is released from the metal support surface.

The invention also includes a method of detecting the presence or assessing of the severity of a disease, disorder or abnormal physical state in a mammal. The method includes the steps of: (a) administering an effective amount of a compound useful for generating a complex-forming metal ion labeled agent; and (b) detecting the presence or assessing the severity of the disease, disorder or abnormal physical state. Another embodiment includes a method of radiotherapy of a disease, disorder or abnormal physical state in a mammal including the steps of administering an effective amount of a compound useful for generating a complex-forming metal ion labeled agent.

The invention also includes a method for the preparation of a support surface for manufacturing a complex-forming metal labeled agent including electro or electroless metal plating or vapor deposition of a suitable thickness, of the metal onto an inorganic or polmeric substrate in the form of particles, sponges or sieves, fibers or surfaces with suitable surface area between about 1 and 10,000cm$^2$. 
BRIEF DESCRIPTION OF THE FIGURES

Preferred embodiments of the invention will be described in relation to the drawings in which:

Figure 1 (a) is a schematic figure showing transchelation of a conjugate (including surface binding group (SBG) and three accessory groups (AG)) from a metal support surface to a complex-forming metal (CFM);

Figure 1(b) a schematic figure showing transchelation of a conjugate from a gold surface to technetium.

Figure 2 is a schematic figure showing in situ production of a thiol bound to a gold surface

Figure 3 is a radiometric trace of Tc-99m RP895(1) (Labeling of RP414)

Figure 4 is a ultraviolet light trace of Tc-99m RP895(1)

DETAILED DESCRIPTION OF THE INVENTION

The present invention simplifies the process of generating a metal-ligand complex by coupling a conjugate to a support surface and transchelating the conjugate from the solid support to the metal. In a preferred embodiment, transchelation is from gold to technetium. The support surface preferably includes gold or an element having properties of binding to the metal cleavable conjugate that are similar to gold (gold is preferably Au(111)) so that a metal labeled radiotherapeutic agent or imaging agent can be formed. Metals with properties similar to gold include silver and copper. Preferably, the support surface is at least 50% metal, at least 90% metal and most preferably substantially pure metal (i.e. at least 99.9% metal). The support surface is preferably solid but may be semi-solid (for example, gold may be vapor deposited on a semi-solid compound, such as a soft plastic or resin). The step of introducing a metal to the support surface results not only in the formation of metal-support surface complexes, but also in the consequential release of those complexes from the support for collection in a form substantially free of uncomplexed conjugate. These processes are shown in Figures 1(a) and 1(b). Articles that describe materials and methods for binding molecules to gold include Bain et al., "Formation of

The present invention also permits the \textit{in situ} formation of the bound thiol through binding to a gold surface. The protected sulfur atom binds to the gold surface resulting in the release of the protecting group as shown in Figure 2.

\textbf{Compound Aspects}

According to an aspect of the present invention, compounds are provided that are useful for generating metal labeled imaging agents that are substantially free of the unlabeled imaging agent. The compounds include a metal support surface, and a conjugate releasably bound to the support surface. The conjugate is capable of coordinating with a complex-forming metal ion so that the conjugate is released (transchelated) from the support surface. The conjugate preferably includes a ligand and a targeting molecule. The conjugate is preferably a peptide, a polypeptide, a peptide or polypeptide mimetic (preferably a derivative) or an organic molecule. Those skilled in the art recognize that a variety of techniques are available for constructing peptide mimetics with the same or similar desired biological activity as a corresponding peptide or polypeptide compound of the invention but with more favorable activity with respect to solubility, stability, and/or susceptibility to hydrolysis and proteolysis. See for example, Morgan and Gainor, \textit{Ann. Rep. Med. Chem.}, 24:243-252 (1989). The organic molecule is preferably a small organic molecule, having molecular weight less than about 600 Daltons and more preferably less than about 500 Daltons. The ligand may be a peptide, a peptide mimetic or a small organic molecule. The ligand preferably incorporates (a) a surface binding group selected from the group consisting of a cysteine amino acid residue, a cysteine amino acid residue derivative, a thiol or thioether group attached to an organic molecule,
an amino acid residue derivative including phosphorous and a phosphorous containing organic molecule, wherein the amino acid residue, amino acid residue derivative or organic molecule is capable of releasably binding to the support surface; and (b) at least one accessory group capable of coordinating with the complex-forming metal ion. In a variation of the invention it is possible that one or more accessory groups is in the targeting molecule. The conjugate is capable of coordinating with a complex-forming metal ion so that the conjugate is released from the support surface. The conjugate preferably includes a peptide sequence such as a bombesin 7-14 fragment, QWAVGHLM, TKPPR, RGDS, cyclopropylcarbonyl-nLe-L-F-W-E-K(GCSDMG)-G, an antibody (preferably monoclonal or polyclonal) antibody fragment and small organic molecule that targets a receptor or a transporter.

The compound may optionally include a linker, which is, preferably, a biologically inert organic residue connecting the targeting molecule and the conjugate. Suitable linkers are alkyll, polyether, aromatic or polyaromatic compounds, with 3-100 atoms.

These compounds are useful for generating compositions (preferably imaging agent compositions or radiotherapeutic pharmaceutical compositions) with very high specific activity because they are substantially free of unlabeled agent.

**Ligand Definition**

The term "ligand" refers to compounds that incorporate at least one surface binding group. A surface binding group includes a sulfur or phosphorous atom (or atom with similar binding properties) which releasably binds to the support surface. In a preferred embodiment, the atom is sulfur which is capable of binding to gold to become a sulfide. The ligand also includes at least one accessory group, and preferably three of the accessory groups, capable of forming a coordinate bond with a given complex-forming metal, thereby forming a stable metal-ligand complex. The ligand preferably incorporates 3 accessory groups selected from the group consisting of (a) a nitrogen atom, an oxygen atom or a sulfur atom incorporated in an amino acid residue, (b) a nitrogen atom, an oxygen atom, a selenium atom, a phosphorous atom or a sulfur atom incorporated in an amino acid residue derivative, or (c) a nitrogen atom, an oxygen atom, a selenium atom, a phosphorous atom or a sulfur atom incorporated in an organic molecule or (d) a combination of one or more of (a) to (c), wherein the atoms have metal coordinating activity.
In the case where a ligand contains one accessory group and a surface binding group, the ligand may be referred to as a "chelator". Ligands that contain two or more accessory groups and a surface binding group, referred to as multidentate, typically form more stable metal-ligand complexes than do monodentate ligands and are preferred for this reason.

Many ligands that bind to radionuclide metals are tetradoentate containing a combination of four nitrogen and sulfur metal-coordinating atoms i.e. N₂S and N₂S₂, however they may incorporate other metal-coordinating atoms such as oxygen, phosphorous and selenium (for example see Figure 1(a)). Preferred ligands of the invention include molecules incorporating a sulfur surface binding atom and at least 3 nitrogen atoms (for example see Figure 1(b)). The ligand preferably includes a peptide selected from the group consisting of a tetradoentate N₄S₄ ligand, a tetradoentate N₄S₄ ligand derivative, a polyamino polysulfide and a polyamino polysulfide derivative.

For radiotherapy and diagnostic imaging it is particularly desirable that the metal complex is highly stable \textit{in vivo} so that the metal is not released from the ligand in substantial quantities to accumulate in tissues. The present invention can be applied to a wide variety of ligands, such as N₂S chelators described in PCT application PCT/CA94/00395 and N₂S₂ chelators described in PCT application PCT/CA94/00479. Preferred ligands are peptides or derivatives thereof which incorporate a pendant sulfhydryl group for binding to a metal. Suitable peptidic chelators are those described in WO 9317719 which are amenable to coupling to targeting molecules, particularly targeting molecules that are also peptidic. In one embodiment, the invention is applied to label ligands that have intrinsic targeting properties. One such ligand available for radiodiagnostic imaging is mercapto-acetyl-glycyl-glycyl-glycine (MAG3) which localizes in renal tissue and may be labeled according to the method of the present invention to prepare renal imaging or radiotherapeutic agents.

MAG3 is an N₂S class of ligand having three nitrogen coordinating atoms and one sulfur coordinating atom.

**Targeting Molecule**

Targeting molecules suitable for use in compounds of the invention are compounds that are capable of localizing selectively \textit{in vivo} at sites for imaging such as at a particular organ, tissue or cell type. Suitable targeting molecules include a polypeptide, a peptide, a nucleic acid molecule, an oligonucleotide, a saccharide, an oligosaccharide, a steroid, a cyclic peptide, a peptide or polypeptide mimic, an enzyme substrate, an inhibitor and a
small organic molecule. Preferred targeting molecules include polypeptides and peptides, particularly those capable of binding with specificity to cell surface receptors characteristic of a particular pathology. The targeting molecule is preferably a molecule having agonist or antagonist activity. The targeting molecule preferably includes a molecule selected from the group consisting of a bombesin 7-14 fragment, QWAVGHLM, TKPPR, RGDS and small organic molecule that targets a receptor or a transporter. The receptor or transporter is preferably a dopamine receptor or transporter, a serotonin receptor or transporter, a sigma receptor, a GABA receptor, a nicotinic receptor, a cholinergic receptor, a norepinephrine receptor or transporter, a glucose transporter and an opioid receptor. Other preferable targeting molecules are peptides, polypeptides or derivatives comprising 3 or more amino acid residues that bind to cell surface receptors such as those described in PCT/CA94/00395. Preferably, targeting molecules are peptides comprising about: 3 to 1000, 3 to 500, 3 to 100, 3 to 50 amino acids and more preferably 3 to 10 or 3 to 6 amino acids. Small organic molecules of preferably about: 6 to 500, 6 to 250, 6 to 100 carbons and more preferably about 6 to 50 or 6 to 25 carbons are also useful targeting molecules.

In an embodiment, targeting molecules are chemotactic peptides that bind to cell surface receptors and in particular are chemotactic peptides that incorporate the amino acid sequence cyclopropylcarbonyl-nLe-L-F-W-E-K(GCSDMG)-G.

In the particular process aspect of the invention, it is desirable that the targeting molecule itself be free of metal binding sites such as pendant sulfhydryl groups. A ligand-targeting molecule conjugate labeled according to this particular process wherein the targeting molecule presents metal binding sites such as pendant sulfhydryl groups found in cysteine residues may 1) lose some or all of its localizing activity and 2) release metal in vivo thereby increasing background noise and obscuring the image.

Ligands and/or targeting molecules that are peptidic are commercially available or may be synthesized de novo by solid phase techniques or by recombinant DNA techniques. Solid-phase peptide synthesis generally involves the use of automated synthesizers and an appropriate support as the solid phase, to which is attached the C-terminal amino acid of the desired peptide. Extension of the peptide in the N-terminal direction is then achieved by successively coupling a suitably protected form of the next desired amino acid, using either FMOC- or BOC-based chemical protocols typically, until synthesis is complete. Protecting groups are then cleaved from the peptide, usually simultaneously with cleavage of the peptide from the support, and the peptide is then isolated. Common purification techniques...
include reversed-phase HPLC using acetonitrile as solvent and trifluoroacetic acid as an ion-pairing agent. Procedures are described in numerous publications. Reference may be made to Stewart and Young, *Solid Phase Peptide Synthesis*, 2nd Edition (and subsequent editions), 1984, Pierce Chemical Company, Rockford, Illinois which is incorporated by reference in its entirety. Alternatively, peptides may be synthesized in solution or on a solid phase in small blocks and subsequently ligated to give the desired sequence. Peptides incorporating amino acids that are not genetically encoded require synthetic techniques for preparation.

**Support**

The term "support surface" refers to any substrate that is insoluble and inert in labeling solutions and is a metal support surface which is either made of, or is coated with, gold, silver or copper or a metal capable of releasably binding and coordinating sulfur or phosphorous for forming a metal complex in preparation of labeled agents. Suitable compounds that may be coated with a metal include include inorganic silicate glass, alkylamino functionalized controlled-pore glass, silica or alumina beads and organic polystyrene, polyacrylamide or sugar polymers such as Sephadex and agarose. The support surface may be provided as a powder, a solid piece of metal, a ball contained in a tube or as a coating on the inside of a vessel. For the purposes of generating metal-ligand complexes the metal support may be in a column that allows for easy passage, collection and filtration of the complex solution.

The invention also includes a method for the preparation of a support surface for manufacturing a complex-forming metal labeled agent comprising electro or electroless metal plating or vapor deposition of a suitable thickness of the metal onto a preferably inorganic or polymeric substrate in the form of particles, sponges or sieves, fibers or surfaces with suitable surface area preferable between about 1 and 10,000cm². The thickness of the metal on the metal support surface is preferably greater than about 10nm.

**Metal**

The term "complex-forming metal" refers to any metal atom that is in a state capable of forming stable coordination bonds with metal coordinating atoms of a ligand. Complex-forming metals include the transition metals, lanthanide metals and actinide metals.
Complex-forming metals useful in preparing agents for radiotherapy or imaging are preferably the metals (or radioisotopes of the metals) Tc, Re, Mn, Fe, Co, Ni, Zn, Cd, Mo, W, Cu, Ag, Au, Ti, Hg, Cr and Rh.

For MRI, the complex-forming metal can be a paramagnetic metal atom such as divalent and trivalent chromium, manganese, iron, cobalt, nickel, copper, samarium. The more preferred complex-forming metals for MRI are those exhibiting a strong magnetic moment, such as manganese.

The halide salt, in particular chloride salt, or oxide of these complex-forming metals are forms capable of complexing with a desired ligand and are suitable for the present invention. Radionuclide labeled imaging agents employ complex-forming metal isotopes that include β-emitters such as rhenium-186 and -188; and γ-emitters such as technetium-99m. The complex-forming metal most preferred for radiodiagnostic imaging is technetium-99m due to its advantageous half life of 6 hours and inexpensive preparation from a molybdenum-99 generator. Technetium and rhenium labeling is accomplished by procedures established in the art. Either complex-forming metal may be introduced to the ligand in aqueous solution in oxo, dioxo or nitrido form, for example pertechnetate (\(\text{H}^{\text{67m}}\text{TcO}_4^-\)) or perrhenate, with a suitable reducing agent such as stannous chloride. Technetium may also be reduced by electrochemical reduction. Alternatively, radiodiagnostic agents may be formed by a transchelation reaction which entails use of the complex-forming metal in the form of a weak metal complex such as technetium-gluconate, heptagluconate, tartrate or citrate to give a desired labeled ligand. Transchelation reactions are typically heated to facilitate conversion of technetium from the weak complex to a complex with the ligand, for example in a boiling hot water bath.

**Method Aspects**

According to a method of the present invention, ligand-targeting molecule conjugates are labeled with complex-forming metals to provide a solution substantially free from unlabeled conjugate. The method for generating a complex-forming metal labeled conjugate diagnostic agent or radiotherapeutic agent includes transchelating a conjugate from a metal support surface to a complex-forming metal ion so that the conjugate is released from the support surface. In general, the process comprises the steps of obtaining a compound in which the conjugate is coupled to a support surface via a metal-cleavable surface binding.
group; introducing a complex-forming metal to the support; and collecting the labeled conjugate released from the support. In this process the complex-forming metal forms a coordination bond with the surface binding group and the accessory group(s) of the ligand thereby cleaving the bond between the ligand atom and the support. As a result, only labeled conjugate is released from the support. The complex-forming metal labeled agent has very high specific activity > about 10,000 Ci/mmol with 99m-technetium and > about 3,000 Ci/mmol with 188-rhenium.

In one preferred embodiment, the method for generating a complex-forming metal labeled conjugate diagnostic agent or radiotherapeutic agent, includes (a) obtaining a suitable compound prepared as described in this application and (b) contacting the compound with the complex-forming metal ion to form a coordinate bond between the complex-forming metal ion and the agent so that the complex-forming metal labeled agent is released from the support surface. Preferably, the method includes collecting the complex-forming metal labeled agent so released.

In another embodiment, the gold surface is employed for in situ formation of the bound thiol. This eliminates several steps which are detrimental to subsequent kit formulation. These steps cause difficulties in ensuring sterility.

A preferred method for preparing a complex-forming metal ion labeled agent (e.g. peptide or polypeptide) includes (a) bonding a peptide, polypeptide, peptide mimetic or polypeptide mimic that includes (i) a cysteine amino acid residue, a cysteine amino acid residue derivative or a phosphorous amino acid residue derivative and (ii) at least one accessory group capable of coordinating with the complex-forming metal ion, to a metal support surface by the sulfur atom or phosphorous atom of the residue or derivative and (b) labeling the peptide, polypeptide or mimic with a complex-forming metal so that the metal complexed peptide, polypeptide or mimic is released from the support surface. The peptide, polypeptide, peptide mimetic or polypeptide mimic is preferably between about 3 and 50 amino acid residues or amino acid residue derivatives.
A preferred method for preparing a complex-forming metal ion labeled organic molecule includes (a) bonding an organic molecule that includes (i) a sulfur atom or a phosphorous atom and (ii) at least one accessory group capable of coordinating with the complex-forming metal ion, to a support surface by the sulfur group or the phosphorous atom and (b) labeling the agent with a complex-forming metal so that the metal complex conjugate is released from the support surface. The organic molecule preferably includes between about 6 and 100 carbons.

The preferred support surfaces are as described above and include metals such as gold, silver, copper and a metal capable of releasably binding sulfur or phosphorous for forming a metal ion labeled agent. The complex-forming metal is preferably a metal or radioisotopic form of metal from the group of Tc, Re, Mn, Fe, Co, Ni, Zn, Cd, Mo, W, Cu, Ag, Au, Ti, Hg, Cr and Rh.

The invention also includes the complex-forming metal ion labeled agent product prepared according to a method of the invention.

15 Pharmaceutical compositions

The invention also includes compositions, preferably pharmaceutical compositions for radiotherapy or imaging, including an agent prepared according to a method of the invention. The agents and compositions are preferably prepared without HPLC. The invention provides a composition including an agent (prepared according to a method of the invention, or any other method) which includes 99m-technetium metal labeled agent (preferably prepared on a gold support surface), and which has a specific activity greater than about 10,000 Ci/mmol with 99m-technetium or greater than about 3,000 Ci/mmol with 188-rhenium. The agent is preferably a peptide such as dimethylglycylserinylcysteinylglycine or polypeptide or a mimetic (preferably a derivative) thereof. Pharmaceutical compositions may be formulated according to known techniques.

The invention includes a method of detecting the presence or assessing of the severity of a disease, disorder or abnormal physical state in a mammal comprising: (a) administering an agent or composition of the invention and (b) detecting the presence or assessing the severity of the disease, disorder or abnormal physical state. The presence or severity of the disease, disorder or abnormal physical state is detected or assessed with a technique
selected from the group consisting of positron emission tomography, nuclear magnetic resonance imaging, scintigraphy, single photon emission computed tomography, perfusion contrast echocardiography, ultrafast X-ray computed tomography, and digital subtraction angiography. Preferably, the agent includes a $^{99m}$Tc metal and binds to a receptor and the technique is single photon emission computed tomography. Suitable methods and materials for imaging are described in: Handbook of Nuclear Medicine second ed., 1993, Mosby Press, Frederic I. Datz; Fundamentals of Nuclear Pharmacy third ed., 1992 Springer-Verlag, Gopal B. Saha; Principles and practice of Nuclear Medicine second ed., 1995, Mosby press, Paul J. Early and D. Bruce Sodee; which are incorporated by reference in their entirety.

The invention also includes a method of radiotherapy of a disease, disorder or abnormal physical state in a mammal including administering an agent or composition of the invention. Methods of performing radiotherapy are described in, for example, Principles and Practice of Nuclear Medicine, 2nd Ed., P.J. Early and D.B. Sodee, Chapter 32, which is incorporated by reference in its entirety.

The pharmaceutical compositions are used to treat diseases and provide images in diseases, disorders or abnormal physical states including oncological, neurological, inflammatory, infection, and degenerative diseases. Other diseases, disorders and abnormal physical states will be apparent to those skilled in the art and/or on review of this application or references cited in this application.

Pharmaceutical compositions used for imaging or to treat patients having diseases, disorders or abnormal physical states preferably include an agent of the invention and an acceptable vehicle or excipient (Remington’s Pharmaceutical Sciences 18th ed, (1990, Mack Publishing Company) and subsequent editions). Vehicles include saline and D5W (5% dextrose and water). Excipients include additives such as a buffer, solubilizer, suspending agent, emulsifying agent, viscosity controlling agent, lactose filler, antioxidant, preservative. The compositions may further include a reducing agent, a bulking agent or a pH stabilising agent. There are preferred excipients for stabilizing peptides for parenteral and other administration. The complex-forming metal labeled agent is preferably administered by an intravenous parenteral route. The excipients preferably include serum albumin, glutamic or aspartic acid, phospholipids and fatty acids. Parenteral (injectable) administration is preferred. The methods for the
preparation of pharmaceutically acceptable compositions which can be administered to patients are known in the art.

The pharmaceutical compositions can be administered to humans or animals (preferably mammals). Dosages to be administered depend on individual patient condition, indication of the drug, physical and chemical stability of the drug, toxicity, the desired effect and on the chosen route of administration (Robert Rakel, ed., Conn's Current Therapy (1995, W.B. Saunders Company, USA)). Preferably the amount of complex-forming metal labeled agent administered to the mammal is about 0.01 mcg/kg/minute to 1,000 mcg/kg/minute and more preferably about 0.01 to 50 mcg/kg/minutes.

10 Kits

The invention also includes kits for preparing a complex-forming metal ion labeled agent. The kit preferably includes a metal support surface, a conjugate and a predetermined quantity of a complex-forming metal ion, the conjugate being capable of being releasably bound to the support surface and capable of coordinating with the complex-forming metal ion so that the conjugate is released from the metal support surface. Suitable support surfaces, conjugates and complex-forming metal ions are described in this application or apparent to a person of skill in the art upon reviewing this application. The kit preferably includes a conjugate including a ligand and a targeting molecule. The ligand preferably incorporates (a) a surface binding group selected from the group consisting of a cysteine amino acid residue, a cysteine amino acid residue derivative, an organic thiol or thioether containing molecule, an amino acid residue derivative including phosphorous and a phosphorous containing aliphatic molecule, wherein the amino acid residue, amino acid residue derivative or aliphatic molecule is capable of releasably binding to the support surface; and (b) at least one accessory group. The conjugate is capable of coordinating with a complex-forming metal so that the conjugate is released from the support surface. Preferable targeting molecules are described in this application. The polypeptides, peptides or other reagents may be lyophilized. Since the radioisotopic metals often have a very short half life, it is advantageous to omit them from the kit.

The support surface preferably includes a metal selected from the group consisting of gold, silver, copper and a metal capable of releasably binding sulfur or phosphorous for forming a metal complex. The complex-forming metal is preferably one or more of the
metals and radioisotopic metal forms of Tc, Re, Mn, Fe, Co, Ni, Zn, Cd, Mo, W, Cu, Ag, Au, Ti, Hg, Cr and Rh.

Preferred embodiments of the invention are described below in examples which are not intended to in any way limit the scope of the invention.

5 Example 1 - Preparation of dimethylglycylserinylcysteinylglycine

A solution of dimethylglycylserinylcysteinylglycine (RP414) (50mg) and mercuric acetate (75mg) in 30% acetic acid (2mL) was stirred at room temperature for 3h. Distilled water (2mL) was added and H₂S gas was slowly bubbled through the solution for 3 min causing a black precipitate (mercury sulfide). The solution was filtered through a 0.2 micron filter diluted with a further 2mL of distilled water and lyophilised.

10 Example 2 - Preparation of dimethylglycylserineylcysteinylglycine (RP414-SH) attached to a gold surface.

A piece of gold foil (50 micron thickness) measuring 1 x 5cm was coiled into a spiral and placed into a test tube. To this spiral was added a solution of 20% nitric acid and the whole gently agitated for 2h. The nitric acid was removed and the foil washed with distilled water (5 times 4mL for 30 min each). The final portion of water was removed and the foil soaked in phosphate buffered saline (0.01M) for 1.5h at pH 7. The phosphate was then removed immediately prior to addition of the thiol.

20 A solution of dimethylglycylserinylcysteinylglycine (RP414-SH) prepared as in example 1 (~50mg) in phosphate buffered saline (3mL) was adjusted to pH 7 using KHCO₃ / K₂CO₃ buffer. This solution was added to the foil prepared above and the reaction mixture gently agitated at room temperature for 20h under an argon atmosphere. The solvent was decanted off and the foil washed with successive portions (2mL) of phosphate buffered saline (five portions for 30min each) with gentle agitation. The final aliquot was retained for analysis by HPLC to ensure that all non-adsorbed RP414-SH was removed. The final aliquot was decanted off and the apparatus purged with argon ready for labelling with 99m-Tc. The peptide RP414-SH adsorbed to the gold surface was designated RP895.
Radiolabelling Method of Gold Surface

- 1.0mL of saline was added to the above prepared RP895

- 100μL of stannous gluconate was added (stannous gluconate is prepared by the addition of 20μL of 20mg/mL stannous chloride to 1.0mL of 13mg/mL sodium gluconate)

- approximately 10mCi of Tc-99m pertechnetate in 200μL of saline was added to the reaction

- The reaction vessel was then shaken vigorously

- Allow the reaction to take place for 1 hour at room temperature

- Then incubate reaction for 30 minutes at 60°C

The total reaction volume was 1.3mL, a clear and colourless solution with a pH of 5.0 was achieved.

A 500μL sample was analyzed using high performance liquid chromatography with a reverse phase C-18 column and a step gradient method of 0 to 70% acetonitrile w/0.1% TFA over 25 minutes. The sample was analyzed by both radiometric and UV detectors (see Figure 3 for radiometric and Figure 4 for UV of the final reaction.

Example 3 - Radiolabelling Method for RP414 on Gold Flakes (RP902)

15 – 830 mg of gold flakes loaded with RP414 was soaked in 1.0 ml of saline, followed by the addition of 0.1 ml of stannous gluconate and 0.1 ml of Tc-99m sodium pertechnetate (approximately 10 mCi). The reaction which contains a small stirrer was shaken vigorously and placed on a hot plate/stirrer to be incubated at 60 – 70°C for 1 hour. An aliquot of the reaction mixture was removed and filtered through an acrodisc low protein binding 0.2μm membrane filter. The filtered reaction was then analyzed using HPLC with a reverse phase C18 column and a step gradient of 0.1% TFA in both water and acetonitrile. The sample was analyzed by both radiometric and UV detectors.
Example 4 - Preparation of dimethylglycine-serine-cysteine-glycine on solid support

RP414 (dimethylglycine-serine-cysteine (Acm)-glycine) 50mg was dissolved in 30% acetic acid and mercury acetate (75mg) added. The mixture was stirred at room temperature for 3.5h hydrogen sulfide gas was bubbled through the solution with the formation of a black precipitate. This precipitate was removed by filtration and the solvents removed from the filtrate under reduced pressure.

Gold powder (2 micron average particle size) (75mg) was wetted a drop of methanol in distilled water and the solution removed. The powder was then suspended in 20% nitric acid and shaken at 50C for 1.5h and after settling the supernatant removed. The powder was then washed with distilled water (4 times 5mL for 30 min each) and then washed with phosphate buffered saline (2mL). After removal of the saline a solution of de-protected RP414 in phosphate buffered saline (2mL) was added and the mixture shaken at room temperature under argon for 20h. The supernatant was removed and the gold powder washed with successive portions of phosphate buffered saline (5 times 4mL).

Example 5: Attachment of RP527-SH to Gold Flakes/Spheres (RP904)

Gold powder (1.5-3.0 micron particles, ~100 mg) was flamed using a bunsen burner. Methanol was added to the gold and stirred vigorously to break up the gold into fine powder. The suspension was centrifuged and the solution decanted.

RP527(dimethylglycine-ser-cys(Acm)-gly-βala-gln-trp-alal-val-gly-his-leu-met-NH₂) (~10mg, 1eq) was dissolved in 30% acetic acid (4mL) and then mercuric acetate (2.2 mg) was added. The reaction was left at room temperature for 3 hours and then bubbled through with hydrogen sulfide for 2 minutes. The resulting mixture was centrifuged and the solution decanted from the pellet of mercury sulfide. The solvent was removed in vacuo. RP527-SH (~10 mg) was then dissolved in a 1:1 solution of ethanol:0.01 PBS and added to the gold powder in a vacutainer with vigorous stirring (magnetic stirbar was added). The solution was flushed with argon for 10 minutes and left under argon at room temperature for 24 hours. The reaction mixture was centrifuged and the supernatant removed. The powder was washed with a 1:1 mixture of ethanol:aqueous 0.1% trifluoroacetic acid (5 x 4 mL), centrifuging between each addition of washing solution.
The final aliquot was decanted off and the gold was dried in vacuo. It was purged with argon and stored at -20°C in preparation for labeling with Tc-99m.


100 mg of gold flakes loaded with RP527 was soaked in 1.0 ml of saline, followed by the addition of 0.1 ml of stannous gluconate and 0.1 ml of Tc-99m sodium pertechnetate (approximately 10 mCi). The reaction which contains a small stirrer was shaken vigorously and placed on a hot plate/stirrer to be incubated at 70 - 75°C for 1 hour. An aliquot of the reaction mixture was removed and filtered through an acrodisc low protein binding 0.2μm membrane filter. The filtered reaction was then analyzed using HPLC with a reverse phase C18 column and a step gradient of 0.1% TFA in both water and acetonitrile. The sample was analyzed by both radiometric and UV detectors.

**Example 6: Preparation of RP414 (dmG-S-C(Acm)-G) attached to gold foil (RP895)**

A piece of gold foil (50 micron thickness, 1 cm x 5 cm) was folded into an accordion shape and subsequently shaped into a cylinder. A solution of 20% nitric acid (4 mL) was added to the gold foil and heated at 40°C for 2h. The nitric acid was removed and the foil was washed with distilled water (5 x 4 mL) for a few minutes. RP414 (~50 mg) was dissolved in 30% acetic acid (4 mL) and added to the gold in a vac tube. The solution was flushed with argon and left under argon at room temperature for 24 hours. The supernatant was removed and the foil washed with distilled water (5 x 4 mL). The final aliquot was decanted off and the vac tube was purged with argon in preparation for labeling with Tc-99m.

This experiment was repeated with RP128 (dmG-S-C(Acm)-G-T-K-P-P-R) attached to gold foil (RP905).

**Example 7: Preparation of Kit Formulation for RP895**

A piece of gold foil (50 micron thickness, 1cm x 5 cm) was prepared and washed using the same procedure outlined in Example 1. RP414 (~50 mg) was loaded onto the gold using the same procedure outlined in Example 1. Once washed, labeling solution
consisting of stannous gluconate (100μL), stannous chloride (20μL, 20mg/mL) and sodium gluconate (1mL, 13mg/mL) was added, frozen and lyophilized.

**Example 8: Preparation of RP414 attached to gold powder (RP902)**

Gold powder (1.5-3.0 micron particles, ~75 mg) was wetted with 5% methanol in water. The suspension was centrifuged and the solution decanted. The gold powder was washed with water (4 mL) and centrifuged. The water was decanted and 20% nitric acid was added to the gold. The suspension was heated at 40°C for 2h. The suspension was centrifuged and the nitric acid decanted. The powder was washed with distilled water (5 x 4 mL), each time centrifuging between each addition of water. RP414 (~50 mg) was dissolved in 30% acetic acid (4 mL) and added to the gold powder in a vac tube with vigorous stirring (magnetic stirbar was added). The solution was flushed with argon and left under argon at room temperature for 24 hours. The supernatant was removed and the powder washed with distilled water (5 x 4 mL), centrifuging between each addition of water. The final aliquot was decanted off and the vac tube was purged with argon in preparation for labeling with Tc-99m.

**Example 8a:**

RP902 and RP904 were prepared as described in Example 8. However, the solution in which they were loaded onto the gold powder was changed to 1:1 ethanol:30% acetic acid. The final samples were lyophilized in preparation for labeling with Tc-99m.

**Example 8b:**

Gold powder (~75mg) was loaded with de-protected RP414 in 1:1 ethanol:0.01M PBS. The rest of the reaction was carried out following the procedure in Example 8. This reaction was repeated for de-protected RP527.

**Example 9: Incremental Labeling of RP414 on Gold Powder (RP902)**

A large batch of gold powder (1.5-3.0 micron particles, ~2g) was washed and loaded with RP414 as described in Example 3. Ever increasing amounts were prepared for labeling
with Tc-99m to investigate the efficiency of labeling as the amount of RP414 on gold powder was increased. Amino acid analysis was carried out on this batch of RP902.

Amounts of RP902 submitted for Tc-99m labeling:

7.85mg, 17.9mg, 34.4mg, 78.8mg, 151.3mg and 308.6mg

EXAMPLE 10: METHODS OF RADIOLABELLING GOLD COMPOUNDS WITH Tc-99m PERTECHNETATE

Preparation of Stannous Gluconate:
0.02mL of 20mg/mL stannous chloride was added to 1.0mL of 13mg/mL sodium gluconate and shaken well

1. Radiolabelling Method for RP128 on Gold Foil (RP905)

A piece of RP905 was soaked with 1.5mL of saline in a glass vacutainer. 0.1mL of freshly prepared stannous gluconate was added as well as 0.1mL of Tc-99m pertechnetate (approximately 10mCi). The reaction vessel was shaken vigorously and allowed to sit at room temperature for 1 hour. The final reaction volume was 1.7mL and was clear and colourless with a pH of 4.5 – 5.5. An aliquot of the reaction was analyzed using HPLC with a reverse phase C-18 column and a step gradient method of 0 to 70% acetonitrile w/ 0.1% TFA over 25 minutes. The sample was analyzed by both radiometric and UV detectors.

The same method was repeated with RP414 on gold foil (RP895).

2. Radiolabelling Method for RP527 on Gold Foil (RP900)

A piece of RP900 was soaked with 1.0mL saline in a glass vacutainer, followed by the addition of 0.1mL of stannous gluconate and 1.0mL of Tc-99m pertechnetate (approximately 10mCi). The reaction vessel was shaken vigorously and placed in a water bath for incubation at 55°C for 1 hour. The final reaction solution was clear and colourless with a pH of 4.5 – 5.0. An aliquot of the reaction is analyzed using HPLC with a reverse phase C-18 column and a step gradient method of 0 to 70% acetonitrile w/ 0.1% TFA over 25 minutes. The sample was analyzed by both radiometric and UV detectors (wavelength = 214nm).

SUBSTITUTE SHEET (RULE 26)

75mg of gold powder was loaded with RP414 was soaked in 0.5mL of saline, followed by the addition of 0.1mL of stannous gluconate and 0.1mL of Tc-99m pertechnetate (approximately 10mCi). The reaction was then shaken vigorously and stirred in an oil bath at 55 - 60°C for 1 hour. Care was taken when removing the reaction out of the water bath so as not to disturb the powder, which settled to the bottom of the container. This portion was then filtered through a 0.2μ acrodisc filter to give a clear solution with a pH between 4.5 – 5.0. An aliquot of the reaction was analyzed using HPLC with a reverse phase C-18 column and a step gradient method of 0 to 70% acetonitrile w/ 0.1% TFA over 25 minutes. The sample was analyzed by both radiometric and UV detectors (wavelength = 214nm).

The same method was used for RP527 except the temperature and time of incubation was changed to 100°C for 35 minutes.

The present invention has been described in detail and with particular reference to the preferred embodiments; however, it will be understood by one having ordinary skill in the art that changes can be made without departing from the spirit and scope thereof. For example, where the application refers to peptides, it is clear that polypeptides and proteins may often be used.

All publications, patents and patent applications are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
WE CLAIM

1. A composition for generating a metal ion labeled imaging agent, the composition comprising:

   • a metal support surface; and

   • a conjugate including a metal ion binding moiety and a biological targeting moiety, the metal ion binding moiety including a sulfur atom or a phosphorous atom for binding to the metal support surface,

   wherein the metal ion binding moiety is capable of coordinating with a metal ion when the metal ion binding moiety is bound to the support thereby releasing the labeled conjugate from the support surface.

2. The compound of claim 1, wherein the metal ion binding moiety includes a sulfur atom attached to a sulfur protecting group, the metal support surface being capable of binding to the protected sulfur atom thereby releasing the sulfur protecting group from the sulfur atom and forming a thiol bond with the metal ion binding moiety.

3. The compound of claim 2 wherein the metal support surface is gold.

4. The compound of claim 1, wherein the metal support surface comprises a metal capable of releasably binding sulfur or phosphorous for forming a metal ion labeled agent.

5. The compound of claim 1, wherein the support surface comprises a metal selected from the group consisting of gold, silver and copper.

6. The compound of claim 1, wherein the conjugate comprises a ligand and a targeting molecule wherein the ligand incorporates:

   (a) a surface binding group selected from the group consisting of a cysteine amino acid residue, a cysteine amino acid residue derivative, a thiol or thioether group attached to an organic molecule, an amino acid residue derivative

   25
including phosphorous and a phosphorous containing organic molecule, wherein
the amino acid residue, amino acid residue derivative or organic molecule is
capable of releasably binding to the support surface; and

(b) at least one accessory group capable of coordinating with the complex-
forming metal ion;

wherein the conjugate is capable of coordinating with a complex-forming metal
ion so that the conjugate is released from the support surface.

7. A compound useful for generating a complex-forming metal ion labeled agent, the
compound comprising: a metal support surface capable of releasably coordinating to
sulfur or phosphorus, and a conjugate releasably bound to the support surface, the
conjugate comprising a ligand and a targeting molecule wherein the ligand incorporates

(a) a surface binding group selected from the group consisting of a cysteine
amino acid residue, a cysteine amino acid residue derivative, a thiol or thioether
group attached to an organic molecule, an amino acid residue derivative
including phosphorous and a phosphorous containing organic molecule, wherein
the amino acid residue, amino acid residue derivative or organic molecule is
capable of releasably binding to the support surface; and

(b) at least one accessory group capable of coordinating with the complex-
forming metal ion;

wherein the conjugate is capable of coordinating with a complex-forming metal
ion so that the conjugate is released from the support surface.

8. The compound claim 7, wherein the ligand comprises a peptide, a peptide mimetic, a
polypeptide, a polypeptide mimetic or a small organic molecule.

9. The compound of any of claims 7 or 8 wherein the targeting molecule comprises a
molecule having agonist or antagonist activity selected from the group consisting of a
polypeptide, a peptide, a nucleic acid molecule, an oligonucleotide, a saccharide, an

26

SUBSTITUTE SHEET (RULE 26)
oligosaccharide, a steroid, a cyclic peptide, a peptide or polypeptide mimetic, an enzyme substrate, an inhibitor and a small organic molecule.

10. The compound of any of claims 7 to 9, wherein the targeting molecule comprises a peptide, a polypeptide, a peptide or polypeptide mimetic or a small organic molecule.

11. The compound of any of claims 1 to 10, wherein the conjugate comprises a peptide, a polypeptide, a peptide or polypeptide mimetic or a small organic molecule.

12. The compound of any of claims 7 to 11, wherein the ligand comprises a peptide selected from the group consisting of a tetradeutate $N_xS_{4-x}$ ligand, a tetradeutate $N_xS_{4-x}$ ligand derivative, a polyamino polysulfide and a polyamino polysulfide derivative.

13. The compound of any of claims 1 to 12, wherein the targeting molecule comprises a molecule selected from the group consisting of a bombesin 7-14 fragment, QWAVGHLM, TKPPR, RGDS and a small organic molecule that targets a receptor or a transporter.

14. The compound of any of claims 1 to 13, wherein the conjugate comprises a peptide sequence selected from the group consisting of a bombesin 7-14 fragment, QWAVGHLM, TKPPR, RGDS and small organic molecule that targets a receptor or a transporter.

15. The compound of claim 13 or 14, wherein the receptor or transporter is selected from the group consisting of a dopamine receptor or transporter, a serotonin receptor or transporter, a sigma receptor, a GABA receptor, a nicotinic receptor, a cholinergic receptor, a norepinephrine receptor or transporter, a glucose transporter and an opioid receptor.

16. The compound of any of claims 7 to 15, wherein the ligand incorporates 3 accessory groups selected from the group consisting of (a) a nitrogen atom, an oxygen atom or a sulfur atom incorporated in an amino acid residue, (b) a nitrogen atom, an oxygen atom, a selenium atom, a phosphorous atom or a sulfur atom incorporated in an amino acid residue derivative, or (c) a nitrogen atom, an oxygen atom, a selenium atom, a phosphorous atom or a sulfur atom incorporated in an organic molecule or (d) a
combination of one or more of (a) to (c), wherein the residues, derivatives and/or molecules have metal coordinating activity.

17. The compound of claim 16, wherein the metal support surface comprises a metal selected from the group consisting of gold, silver and copper.

18. The compound of any of claims 1 to 17, wherein the complex-forming metal is selected from the group of metals and radioisotopic metals consisting of Tc, Re, Mn, Fe, Co, Ni, Zn, Cd, Mo, W, Cu, Ag, Au, Ti, Hg, Cr and Rh.

19. The compound of any of claims 1 to 17, wherein the complex-forming metal is selected from the group of metals and radioisotopic metals consisting of Tc, Cu and Re.

20. A method for generating a complex-forming metal ion labeled diagnostic agent or radiotherapeutic agent, comprising the steps of: (a) providing a compound according to any of claims 1 to 19; (b) contacting the compound with the complex-forming metal ion to form a coordinate bond between the complex-forming metal ion and the agent so that the complex-forming metal labeled agent is released from the support surface.

21. The method of claim 20, further comprising collecting the complex-forming metal labeled agent so released.

22. A method for generating a complex-forming metal ion labeled diagnostic agent or radiotherapeutic agent, comprising the step of transchelating a conjugate from a metal support surface to a complex-forming metal ion so that the conjugate is released from the metal support surface.

23. A method for preparing a complex-forming metal ion labeled peptide comprising (a) bonding a peptide, polypeptide, peptide mimic or polypeptide mimic that includes (i) a cysteine amino acid residue, a cysteine amino acid residue derivative or a phosphorous amino acid residue derivative and (ii) at least one accessory group capable of coordinating with the complex-forming metal ion, to a metal support surface by the sulfur atom or phosphorous atom of the residue or derivative and (b)
labeling the peptide, polypeptide or mimetic with a complex-forming metal so that the metal complexed peptide, polypeptide or mimetic is released from the support surface.

24. The method of claim 34, wherein peptide, polypeptide, peptide mimetic or polypeptide mimetic is between about 3 and 50 amino acid residues or amino acid residue derivatives.

25. A method for preparing a complex-forming metal ion labeled agent comprising the steps of (a) bonding an organic molecule that includes (i) a sulfur atom or a phosphorous atom and (ii) at least one accessory group capable of coordinating with the complex-forming metal ion, to a support surface by the sulfur atom or the phosphorous atom and (b) labeling the agent with a complex-forming metal so that the metal complex conjugate is released from the support surface.

26. The method of claim 25, wherein the peptide, polypeptide, peptide mimetic or polypeptide mimetic is between about 3 and 50 amino acid residues or amino acid residue derivatives.

27. The method of any of claims 22 to 26, wherein the support surface comprises a metal selected from the group consisting of gold, silver, copper and a metal capable of releasably binding sulfur or phosphorous for forming a metal complex; and the complex-forming metal is selected from the group of metals and radioisotopic metals consisting of Tc, Re, Mn, Fe, Co, Ni, Zn, Cd, Mo, W, Cu, Ag, Au, Ti, Hg, Cr and Rh.

28. A method for preparing a complex-forming metal ion labeled agent comprising the steps of (a) providing a conjugate including a metal ion binding moiety and a biological targeting moiety, the metal ion binding moiety including a sulfur atom for binding to the metal support surface, the sulfur atom being protected by a sulfur protecting group, (b) contacting the protected sulfur atom with the metal support surface so that the sulfur atom forms a thiol bond with the metal surface thereby releasing the sulfur protecting group and (c) contacting the metal ion binding moiety with the complex-forming metal ion to form a coordinate bond between the complex-forming metal ion and the metal ion binding moiety so that the complex-forming metal labeled agent is released from the support surface.
29. A method according to claim 28 wherein the metal support surface is gold.

30. A complex-forming metal ion labeled agent prepared according to the method of any of claims 20 to 29.

31. A composition for radiotherapy or imaging, comprising the agent of claim 30 and a carrier.

32. The composition of claim 31, further comprising an agent selected from the group consisting of a reducing agent, a bulking agent and a pH stabilising agent.

33. A pharmaceutical composition for radiotherapy or imaging, comprising the agent of claim 30 and a pharmaceutically suitable carrier.

34. A kit for preparing a complex-forming metal ion labeled agent, the kit comprising a metal support surface, a conjugate and a predetermined quantity of a complex-forming metal ion, the conjugate being capable of being releasably bound to the support surface and capable of coordinating with the complex-forming metal ion so that the conjugate is released from the metal support surface.

35. The kit of claim 34 wherein the conjugate includes a sulfur atom attached to a sulfur protecting group, the metal support surface being capable of binding to the protected sulfur atom thereby releasing the sulfur protecting group from the sulfur atom and forming a thiol bond with the conjugate.

36. The kit of claim 35, wherein the conjugate comprises a ligand and a targeting molecule wherein the ligand incorporates

(a) a surface binding group selected from the group consisting of a cysteine amino acid residue, a cysteine amino acid residue derivative, an organic thiol or thioether containing molecule, an amino acid residue derivative including phosphorous and a phosphorous containing aliphatic molecule, wherein the amino acid residue, amino acid residue derivative or aliphatic molecule is capable of releasably binding to the support surface; and
(b) at least one accessory group.

wherein the conjugate is capable of coordinating with a complex-forming metal so that the conjugate is released from the support surface.

37. The kit of claim 34 or 35, wherein the support surface comprises a metal selected from the group consisting of gold, silver, copper and a metal capable of releasably binding sulfur or phosphorous for forming a metal complex; and the complex-forming metal is selected from the group of metals and radioisotopic metals consisting of Tc, Re, Mn, Fe, Co, Ni, Zn, Cd, Mo, W, Cu, Ag, Au, Ti, Hg, Cr and Rh.

38. The kit of claim 34 or 35 further comprising an agent selected from the group consisting of a reducing agent, a bulking agent and a pH stabilising agent.

39. A method of detecting the presence or assessing of the severity of a disease, disorder or abnormal physical state in a mammal comprising: (a) administering an effective amount of the agent or composition of any claims 30 to 32; and (b) detecting the presence or assessing the severity of the disease, disorder or abnormal physical state.

40. A method of radiotherapy of a disease, disorder or abnormal physical state in a mammal comprising administering an effective amount of the agent or composition of any claims 30 to 32.

41. The method of claim 39 or 40, wherein the complex-forming metal labeled imaging agent is administered by an intravenous route.

42. The method of any claims 39 to 41, wherein the amount of complex-forming metal labeled agent administered to the mammal is about 0.01 mcg/kg/minute to 1,000 mcg/kg/minute.

43. The method of claim 42, wherein the amount of complex-forming metal labeled agent administered to the mammal is about 0.01 to 50 mcg/kg/minutes.

44. The method of any of claims 39 to 43, wherein the mammal is a human.
45. The method of any of claims 39 to 44, wherein the disease, disorder or abnormal physical state is selected from the group consisting of oncolgical, neurological, inflammatory, infection, and degenerative diseases, disorders and abnormal physical states.

46. The method of claim 45, wherein the presence or severity of the disease, disorder or abnormal physical state is detected or assessed with a technique selected from the group consisting of positron emission tomography, nuclear magnetic resonance imaging, scintigraphy, single photon emission computed tomography, perfusion contrast echocardiography, ultrafast X-ray computed tomography, and digital subtraction angiography.

47. The method of claim 46, wherein the agent comprises a $^{99m}$Tc metal and the agent binds to a receptor and the technique is single photon emission computed tomography.

48. A composition comprising a technetium metal labeled agent, wherein the composition includes a specific activity greater than 10,000 Ci/mmol with 99m-technetium and greater than 3,000 Ci/mmol with 188-rhenium.

49. The composition of claim 48, wherein the agent is a peptide or polypeptide or a mimetic thereof.

50. The composition of claim 49, wherein the peptide comprises dimethylglycylserinylcysteinylglycine.

51. A method for the preparation of a support surface for manufacturing a complex-forming metal labeled agent comprising electro or electroless metal plating or vapor deposition of a suitable thickness, of the metal onto an inorganic or polmeric substrate in the form of particles, sponges or sieves, fibers or surfaces with suitable surface area between about 1 and 10,000cm$^2$.

52. The method of claim 51, wherein the thickness of the metal on the metal support surface is greater than about 10nm.
53. A pharmaceutical composition for radiotherapy or imaging, comprising a carrier and a complex-forming metal ion labeled agent, wherein the agent is prepared without HPLC.
Fig. 1(a)

SBG = Surface Binding Group
AG = Accessory Group
CFM = Complex Forming Metal
Fig 1(b)
Figure 2
Figure 3
A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A6I K51/08

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:

Electronic data base consulted during the international search (name of data base and, where practical, search terms used):

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 96 03427 A (GOODBODY ANNE; POLLAK ALFRED (CA); RESOLUTION PHARM INC (CA)) 8 February 1996 (1996-02-08) claims</td>
<td>1-53</td>
</tr>
<tr>
<td>Y</td>
<td>WO 93 17719 A (DIATECH INC) 16 September 1993 (1993-09-16) claims 1,26-29</td>
<td>1-53</td>
</tr>
<tr>
<td>P,X</td>
<td>WO 99 40947 A (ESIMA DENNIS; POLLAK ALFRED (CA); THORNBAC JOHN (CA); FAUCONNIER) 19 August 1999 (1999-08-19) claims</td>
<td>1-53</td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

"A" document defining the general state of the art which is not considered to be of particular relevance
"A" document defining the general state of the art which is not considered to be of particular relevance
"B" earlier document but published on or after the international filing date
"C" document which may throw doubts on priority claims or which is cited to establish the publication date of another document or other special reasons (as specified)
"D" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents. Such combination being obvious to a person skilled in the art
"Ø" document member of the same patent family

Date of the actual completion of the international search:

14 December 1999

Date of mailing of the international search report:

28/12/1999

Name and mailing address of the ISA

European Patent Office, P. B. 5018 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31) 70 340-2040, Fax (+31) 70 340-3016

Authorized officer

Berte, M
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>SMITH, C. J. (1) ET AL: &quot;Evaluation of a novel N3S chelation system for the</td>
<td>1-53</td>
</tr>
<tr>
<td></td>
<td>preparation of Tc-99m and Re-188 labeled biomolecules.&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEETING INFO.: 45TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE TORONTO,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ONTARIO, CANADA JUNE 7-11, 1998 SOCIETY OF NUCLEAR MEDICINE. , XP002125500</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>WONG, ERNEST (1) ET AL: &quot;Synthesis and structural characterization of Tc-99m and</td>
<td>1-53</td>
</tr>
<tr>
<td></td>
<td>Re oxo complexes with N-1N'2S-1 peptidic ligands.&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JOURNAL OF NUCLEAR MEDICINE, (1997) VOL. 38, NO. 5 SUPPL., PP. 184P. MEETING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INFO.: 44TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE SAN ANTONIO,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TEXAS, USA JUNE 1-5, 1997 , XP002125501, page 184P, paragraphs NO.,790</td>
<td></td>
</tr>
<tr>
<td></td>
<td>claims 1,32,33</td>
<td></td>
</tr>
</tbody>
</table>
**INTERNATIONAL SEARCH REPORT**

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 
   - because they relate to subject matter not required to be searched by this Authority, namely: 
     - See **FURTHER INFORMATION SHEET PCT/ISA/210**

2.☐ Claims Nos.: 
   - because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.☐ Claims Nos.: 
   - because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2.☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.☐ As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.: 

4.☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 

**Remark on Protest**

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.
Continuation of Box I.1

Although claim(s) 39,41-47 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 40-47 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 9940947 A</td>
<td>19-08-1999</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>

From PCT/ISA/210 (patent family annex) (July 1992)